Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.regg.2010.11.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of age of onset on the course of chronic schizophrenia: factors associated with first hospitalization in a large-scale cross-sectional study.
Eur Arch Psychiatry Clin Neurosci
January 2025
Hefei Fourth People's Hospital, Anhui Mental Health Center, 316 Huangshan Road, Hefei, 230022, China.
This study aims to identify the factors influencing the age of first hospitalization in patients with chronic schizophrenia, focusing on clinical features and blood parameters. A total of 1271 patients diagnosed with chronic schizophrenia were recruited from 17 psychiatric hospitals across China. Demographic and clinical data, including age of first hospitalization, were collected.
View Article and Find Full Text PDFDifferentiating aspects of oral and long-acting injectable antipsychotic drugs for tailoring the therapy of schizophrenia in clinical practice: a narrative review.
Int Clin Psychopharmacol
January 2025
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa.
Schizophrenia is a serious psychiatric condition requiring continuous treatment with antipsychotic medications available in different formulations, including oral antipsychotics (OAPs) and long-acting injectables (LAIs). This narrative review aims to comprehensively outline the advantages and disadvantages of OAPs and LAIs to support clinicians in choosing different formulations based on the presentation of clinical symptoms. An electronic search of the PubMed database was performed in June 2024, and additional articles were retrieved from the references or personal knowledge of the authors.
View Article and Find Full Text PDFSuccessful Clozapine Treatment for Treatment-Resistant Schizophrenia With Zinc Deficiency Severe Anemia: A Case Report.
Neuropsychopharmacol Rep
March 2025
Department of Neuropsychiatry, School of Medicine, Wakayama Medical University, Wakayama, Wakayama, Japan.
Introduction: Clozapine is an atypical antipsychotic drug approved for treatment-resistant schizophrenia (TRS). Despite its high efficacy for TRS, clozapine is associated with several serious adverse effects, such as neutropenia and diabetes, so it requires vigilant monitoring. Severe anemia has also been documented as a rare but serious complication with an unclear mechanism.
View Article and Find Full Text PDFCross-titration from risperidone to clozapine utilizing clozapine serum concentrations: A case report.
Pharmacotherapy
January 2025
Department of Pharmacy Practice, School of Pharmacy, Westbrook College of Health Professions, University of New England, Portland, Maine, USA.
Introduction: Clozapine and risperidone are second-generation antipsychotics used in the treatment of schizophrenia. There are no guidelines on cross-titration of antipsychotics and, additionally, there is a paucity of published data to support the potential utility of using serum drug levels to guide dosing in these situations.
Case Report: A 68-year-old female patient with a history of schizophrenia, taking risperidone and fluoxetine, and a recent diagnosis of Parkinson's disease was admitted to the hospital after a fall at home.
Second-generation antipsychotic-induced dystonia: Analysis using the Japanese Adverse Drug Event Report (JADER) database.
Psychiatry Clin Neurosci
January 2025
Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Aim: This study aimed to explore the comparative risks for dystonia among different second-generation antipsychotics (SGAs), the influence of sex, and the relationship between the time-to-onset of dystonia and its outcomes.
Methods: We analyzed data from the Japanese Adverse Drug Event Report database from April 2004 to November 2023. Cases involving oral SGAs, excluding clozapine, were extracted.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!